Doris Hansen is a Hematology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 248 publications with 1,945 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-6162Provider last certified this registry record 5 Aug 2025.
Clinical trials
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Legend Biotech USA Inc.Program year20254 payments$15,325openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202513 payments$12,973openpaymentsdata.cms.gov ↗
- Celgene CorporationProgram year20254 payments$11,872openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$2,068,249R01CA281756 - Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$690,260R01CA281756 - Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
H. Lee Moffitt Cancer Ctr & Res Inst
FY2024$691,118R01CA281756
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
2025 - Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
Blood Cancer Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Peter Forsyth, MD
Moffitt Cancer Center
Eric Haura, MD
Moffitt Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”